Strong contract wins build commercial momentum
Summary by AI BETAClose X
14 November 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Strong contract wins continue to build commercial momentum
New contracts bring total binding FY26 order book to £1.95 million to date
Fourth consecutive engagement with top 5* global pharmaceutical company underpins technology validation
Strategic IP retention expanding high-value royalty pipeline
Full year revenue expected to exceed prior year
Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce two key contract wins worth £192,000, demonstrating momentum with major global pharmaceutical companies and commercial traction with the proprietary Optimer® platform.
Building commercial momentum with global pharma
With these contract wins, the order book for FY26 has reached £1.95 million, representing a strong pipeline of revenue-generating projects across multiple top-tier pharmaceutical partners. Many of these are repeat contract wins, build on the Group's previous successes with major global companies, which routinely invest in US$100+ million therapeutics, validating the commercial potential of Aptamer's technology platform.
The latest contracts include:
· Repeat contract with top 5 global pharmaceutical company
Fourth successive engagement with this leading pharmaceutical partner and will deliver Optimer® binders for enhanced bioanalysis of neurological samples. The repeat business underscores this partner's confidence in the Optimer® platform's ability to deliver superior performance where traditional antibody technologies have proven insufficient.
· New customer
Contract to deliver binders targeting a protein associated with acute myeloid leukaemia (AML) for use as diagnostic tools and to support future therapeutic studies, expanding Aptamer's presence in high-value oncology applications.
Dual revenue strategy delivering results
These new contracts, coming on top of a series of wins over the past year (see below), reflect Aptamer's strategy to target material future revenues through royalties and monetising IP in the medium to long term, whilst delivering short term revenues and working capital from fee-for-service revenues. The Group's model is to establish relationships with life science companies developing high value therapeutics and assays with fee-for-service contracts, building commercially valuable intellectual property and retaining full ownership of the intellectual property in the developed binders.
FY26 contract pipeline building momentum
Aptamer continues to build commercial momentum with multiple contracts across top-tier pharmaceutical partners, including consistent repeat business with top 5 and top 10 pharma companies. Aptamer is expanding upon the proven strategy of successful platform companies, such as Bicycle Therapeutics, Argenx, and PeptiDream; solving diverse problems as a gateway to larger development opportunities.
The Group's partnerships now span neurology, oncology, and radiopharmaceuticals. This traction is creating pathways to high-value opportunities, as Aptamer evolves from problem-solving for reagent-based projects to high-value therapeutic programmes. The radiopharmaceutical deal with a top 3 pharma partner exemplifies this progression: an initial successful reagent project validated the technology and has now advanced to therapeutic development.
|
Date signed |
|
Partner |
Value |
Start Date |
Completion date |
Application |
|
11 Nov 2025
|
|
New customer
|
£90,000
|
Jan 2026
|
Apr 2026
|
AML diagnostics & potential therapeutic |
|
10 Nov 2025
|
|
Top 5 pharma
|
£102,000
|
Nov 2025
|
Feb 2026
|
Neurological bioanalysis - IPMS |
|
4 Nov 2025
|
|
Top 5 pharma
|
£617,000
|
Dec 2025
|
Mar 2026
|
Neurological bioanalysis - ELISA |
|
13 Oct 2025
|
|
Top 10 pharma
|
£112,000
|
Nov2025
|
Mar 2026
|
Drug target extension
|
|
8 Oct 2025
|
|
Top 3 pharma
|
£360,000
|
Nov 2025
|
Mar 2026
|
Radiopharmaceutical therapeutic development
|
|
Q1 FY26 |
|
Various |
£315,000 |
July-Sep |
Mar 2026 |
Multiple |
|
Brought forward |
|
Various |
£350,000 |
|
Mar 2026 |
Multiple |
|
Total |
|
|
£1.95m |
|
|
|
Outlook
With £1.95 million of binding contracts already secured and seven months remaining in the financial year, the Board is confident that full year revenue will materially exceed the prior year's performance. The Group continues to see strong demand for its Optimer® technology from leading pharmaceutical and biotechnology partners, evidenced by a replenished sales pipeline of £2.9 million following the signing of £0.9 million of deals since the pipeline was last reported at £3.4 million.
The consistent repeat business from top-tier pharmaceutical companies, organisations that invest heavily in developing world-class therapeutics, signals the strategic potential of Aptamer's platform. Each successful engagement not only generates near-term revenue but also adds high-value intellectual property to the Group's expanding portfolio, positioning Aptamer to capture significant long-term value through licensing and royalties.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "These latest contract wins demonstrate the commercial traction we are achieving with our Optimer® platform. Securing our fourth consecutive engagement with a top 5 pharmaceutical company is a strong validation of our technology's performance.
We continue to generate near-term revenue and working capital through fee-for-service contracts while simultaneously building a valuable IP portfolio. Every project we complete adds proprietary binders to our asset base, supporting our strategy to drive long-term shareholder value through licensing, royalties and the progression towards therapeutic partnerships.
We are repeatedly securing business with top-tier pharmaceutical companies with progression to higher value therapeutic applications, as shown in our liver fibrosis and our recent radiopharmaceutical delivery programmes. These partners have countless alternatives, but they choose to work with us repeatedly because our Optimer® binders deliver superior results.
With £1.95 million in binding contracts secured and substantial opportunities in our pipeline, we are confident of exceeding last year's revenue performance and remain focused on continuing to build commercial momentum through the remainder of the financial year."
- Ends -
*Top pharma companies - https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund